INCIPIENT: INtraventricular CARv3-TEAM-E T Cells for PatIENTs With GBM
This study is testing a new type of immunotherapy for glioblastoma, an aggressive brain tumor. The goal is to see how well 'CAR-T' cell therapy—which uses your own reprogrammed immune cells to fight the cancer—works at different dose levels.
This trial is for people with glioblastoma that has returned after initial treatment, or certain newly diagnosed cases. You must have a specific tumor mutation called 'EGFRvIII' to be eligible, and there are specific requirements regarding your past treatments.
If you join, researchers will collect some of your immune cells to modify them in a lab so they can better recognize and attack your tumor. These improved cells are then returned to your body to help your immune system fight the cancer.
The study is currently recruiting participants and is taking place in Boston, Massachusetts. Because this is a Phase 1 study, it is primarily focused on finding the safest and most effective dose for this treatment.
- 1Uses your own cells to help your body fight cancer.
- 2Specifically targets glioblastoma with the EGFRvIII mutation.
- 3Clinical trials offer access to cutting-edge treatments before they are widely available.
No related links yet
Seen this study covered in the news, or found a page that explains it well? Send it over and we'll review it.
Suggest a linkThis summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.